866-997-4948(US-Canada Toll Free)

Hairy Cell Leukemia Pipeline Review, H2 2012

Published By :

Global Markets Direct

Published Date : Oct 2012

Category :

Oncology

No. of Pages : 40 Pages

 

Global Markets Directs, 'Hairy Cell Leukemia Pipeline Review, H2 2012', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Hairy Cell Leukemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hairy Cell Leukemia. Hairy Cell Leukemia Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Hairy Cell Leukemia.
  • A review of the Hairy Cell Leukemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Hairy Cell Leukemia pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.
Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Hairy Cell Leukemia.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Hairy Cell Leukemia pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4

Introduction 5
Global Markets Direct Report Coverage 5
Hairy Cell Leukemia Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Hairy Cell Leukemia 7
Hairy Cell Leukemia Therapeutics under Development by Companies 9
Hairy Cell Leukemia Therapeutics under Investigation by Universities/Institutes 10
Mid Clinical Stage Products 11
Comparative Analysis 11
Early Clinical Stage Products 12
Comparative Analysis 12
Hairy Cell Leukemia Therapeutics Products under Development by Companies 13
Hairy Cell Leukemia Therapeutics Products under Investigation by Universities/Institutes 14
Companies Involved in Hairy Cell Leukemia Therapeutics Development 15
Amgen Inc. 15
MedImmune LLC 16
Hairy Cell Leukemia Therapeutics Assessment 17
Assessment by Monotherapy Products 17
Assessment by Combination Products 18
Assessment by Route of Administration 19
Assessment by Molecule Type 21
Drug Profiles 23
moxetumomab pasudotox - Drug Profile 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Rituximab + Pentostatin - Drug Profile 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Campath + Fludarabine + Cyclosporine + Mycophenolate Mofetil + Peripheral Stem Cell Transplantation - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 26
rituximab - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
2-Chlorodeoxyadenosine + Rituximab - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Cladribine + Rituximab - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Anti-Tac(Fv)-PE38 Immunotoxin - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Rituximab + Bendamustine - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Rituximab + Bendamustine - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Hairy Cell Leukemia Therapeutics Drug Profile Updates 36
Hairy Cell Leukemia Therapeutics Discontinued Products 37
Hairy Cell Leukemia Therapeutics - Dormant Products 38

Appendix 39
Methodology 39
Coverage 39
Secondary Research 39
Primary Research 39
Expert Panel Validation 39
Contact Us 40
Disclaimer 40

List of Table

 
Number of Products Under Development for Hairy Cell Leukemia, H2 2012 7
Products under Development for Hairy Cell Leukemia Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Number of Products under Investigation by Universities/Institutes, H2 2012 10
Comparative Analysis by Mid Clinical Stage Development, H2 2012 11
Comparative Analysis by Early Clinical Stage Development, H2 2012 12
Products under Development by Companies, H2 2012 13
Products under Investigation by Universities/Institutes, H2 2012 14
Amgen Inc., H2 2012 15
MedImmune LLC, H2 2012 16
Assessment by Monotherapy Products, H2 2012 17
Assessment by Combination Products, H2 2012 18
Assessment by Stage and Route of Administration, H2 2012 20
Assessment by Stage and Molecule Type, H2 2012 22
Hairy Cell Leukemia Therapeutics Drug Profile Updates 36
Hairy Cell Leukemia Therapeutics Discontinued Products 37
Hairy Cell Leukemia Therapeutics Dormant Products 38

List of Chart

 
Number of Products under Development for Hairy Cell Leukemia, H2 2012 7
Products under Development for Hairy Cell Leukemia Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Products under Investigation by Universities/Institutes, H2 2012 10
Mid Clinical Stage Products, H2 2012 11
Early Clinical Stage Products, H2 2012 12
Assessment by Monotherapy Products, H2 2012 17
Assessment by Combination Products, H2 2012 18
Assessment by Route of Administration, H2 2012 19
Assessment by Stage and Route of Administration, H2 2012 20
Assessment by Molecule Type, H2 2012 21
Assessment by Stage and Molecule Type, H2 2012 22

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *